Yves Bécouarn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yves Bécouarn has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Marc Ychou
Department of Medical oncology, Montpellier Cancer Institute (ICM), Montpellier University , Montpellier 34298 Cedex 5
4 shared publications J F Seitz
3 shared publicationsR. Guimbaud
3 shared publicationsA. Adenis
2 shared publicationsA. Fourrier-Réglat
2 shared publicationsA. Ravaud
2 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S430
2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S430
2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma
- Open Access
- 19 July 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 297
Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors
Background: Colorectal cancer (CRC) care has improved considerably, particularly since the implementation of a quality of care program centered on national evidence-based guidelines. Formal quality assessment is however still needed. The aim of this research was to identify factors associated with practice variation in CRC patient care. Methods: CRC patients identified from all cancer centers in South-West France were included. We investigated variations in practices (from diagnosis to surgery), and compliance with recommended guidelines for colon and rectal cancer. We identified factors associated with three colon cancer practice variations potentially linked to better survival: examination of ≥12 lymph nodes (LN), non-use and use of adjuvant chemotherapy for stage II and stage III patients, respectively. Results: We included 1,206 patients, 825 (68%) with colon and 381 (32%) with rectal cancer, from 53 hospitals. Compliance was high for resection, pathology report, LN examination, and chemotherapy use for stage III patients. In colon cancer, 26% of stage II patients received adjuvant chemotherapy and 71% of stage III patients. 84% of stage US T3T4 rectal cancer patients received pre-operative radiotherapy. In colon cancer, factors associated with examination of ≥12 LNs were: lower ECOG score, advanced stage and larger hospital volume; factors negatively associated were: left sided tumor location and one hospital district. Use of chemotherapy in stage II patients was associated with younger age, advanced stage, emergency setting and care structure (private and location); whereas under-use in stage III patients was associated with advanced age, presence of comorbidities and private hospitals. Conclusions: Although some changes in practices may have occurred since this observational study, these findings represent the most recent report on practices in CRC in this region, and offer a useful methodological approach for assessing quality of care. Guideline compliance was high, although some organizational factors such as hospital size or location influence practice variation. These factors should be the focus of any future guideline implementation.
- 19 July 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 297
Open AccessQuality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors
Background: Colorectal cancer (CRC) care has improved considerably, particularly since the implementation of a quality of care program centered on national evidence-based guidelines. Formal quality assessment is however still needed. The aim of this research was to identify factors associated with practice variation in CRC patient care. Methods: CRC patients identified from all cancer centers in South-West France were included. We investigated variations in practices (from diagnosis to surgery), and compliance with recommended guidelines for colon and rectal cancer. We identified factors associated with three colon cancer practice variations potentially linked to better survival: examination of ≥12 lymph nodes (LN), non-use and use of adjuvant chemotherapy for stage II and stage III patients, respectively. Results: We included 1,206 patients, 825 (68%) with colon and 381 (32%) with rectal cancer, from 53 hospitals. Compliance was high for resection, pathology report, LN examination, and chemotherapy use for stage III patients. In colon cancer, 26% of stage II patients received adjuvant chemotherapy and 71% of stage III patients. 84% of stage US T3T4 rectal cancer patients received pre-operative radiotherapy. In colon cancer, factors associated with examination of ≥12 LNs were: lower ECOG score, advanced stage and larger hospital volume; factors negatively associated were: left sided tumor location and one hospital district. Use of chemotherapy in stage II patients was associated with younger age, advanced stage, emergency setting and care structure (private and location); whereas under-use in stage III patients was associated with advanced age, presence of comorbidities and private hospitals. Conclusions: Although some changes in practices may have occurred since this observational study, these findings represent the most recent report on practices in CRC in this region, and offer a useful methodological approach for assessing quality of care. Guideline compliance was high, although some organizational factors such as hospital size or location influence practice variation. These factors should be the focus of any future guideline implementation.
- 1 October 2010
- Published by Elsevier in Bulletin du Cancer
- Vol. 97 (4) , S67-S68
R131 Chirurgie des métastases après traitement en première ligne du cancer colorectal par bévacizumab : résultats de la cohorte ETNA
- 1 October 2010
- Published by Elsevier in Bulletin du Cancer
- Vol. 97 (4) , S67-S68
R131 Chirurgie des métastases après traitement en première ligne du cancer colorectal par bévacizumab : résultats de la cohorte ETNA
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 3594
Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.
3594 Background: BV associated with chemotherapy has been demonstrated to improve overall survival (OS) in metastatic CRC (mCRC). This allows to consider secondary resection of metastases for the initially unresectable mCRC. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated in first-line therapy for mCRC were followed for 24 months. Effectiveness for pats with secondary resection of metastases and curative intent is presented here. Results: A total of 411 pts had first-line therapy with BV for mCRC: 347 were analyzable after 24 months of follow-up, and 67 (19.3%) had metastasis resection (pts operated, oPts). oPts main baseline characteristics were: mean age: 61.6 y, male: 46.3%, ECOG 0-1: 91.0% and one metastatic site: 58.2%; those of not operated pts (noPts) were: mean age: 64.0 y, male: 60.0%, ECOG 0-1: 77.5% and one metastatic site: 55.7%. Among the oPts, resection site was: liver n = 44, lung n = 10, other n = 20. Results of surgery available for 56 oPts were: R0-R1: 85.7%, R2: 14.3%. The median time from BV initiation to first resection was 207 days. For oPts, BV was mainly associated with irinotecan-based regimens (97.0%) and with FOLFOX regimens (3.0%); for noPts it was: FOLFIRI: 83.6%, XELIRI: 2.9%, FOLFOX: 10.7%, XELOX: 2.5% and FOLFIRINOX: 0.4%. Objective response rate was 85.1% including 32.8% complete response (vs. 49.3% and 5.4% for noPts), stable disease 14.9% (vs. 30.0%) and absence of progressive disease (vs. 17.1%). Median duration of BV treatment was 6.9 months and of first-line therapy was 14.3 months (vs. 5.0 and 8.3 months for noPts). Median PFS was 13.6 months for oPts, the 1-yr OS rate was 94.0% (95%CI 84.9-97.7) and the 2-yr OS rate was 81.7% (95%CI 70.0-89.2) (vs. for noPts: median PFS 9.0 months, 1-yr OS rate 75.2% [95%CI 69.6-79.8] and the 2-yr OS rate 44.5% [95%CI 38.5-50.4]). Median OS was not reached for oPts and was 21.9 months for noPts. Conclusions: For pts treated by BV in a real-life setting, secondary resection of mCRC for initially unresectable metastases was possible for 19% of pts with 85.7% R0-R1. Evaluation of morbidity and longer follow-up will allow the real long-term benefit to be studied. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 3594
Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.
3594 Background: BV associated with chemotherapy has been demonstrated to improve overall survival (OS) in metastatic CRC (mCRC). This allows to consider secondary resection of metastases for the initially unresectable mCRC. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated in first-line therapy for mCRC were followed for 24 months. Effectiveness for pats with secondary resection of metastases and curative intent is presented here. Results: A total of 411 pts had first-line therapy with BV for mCRC: 347 were analyzable after 24 months of follow-up, and 67 (19.3%) had metastasis resection (pts operated, oPts). oPts main baseline characteristics were: mean age: 61.6 y, male: 46.3%, ECOG 0-1: 91.0% and one metastatic site: 58.2%; those of not operated pts (noPts) were: mean age: 64.0 y, male: 60.0%, ECOG 0-1: 77.5% and one metastatic site: 55.7%. Among the oPts, resection site was: liver n = 44, lung n = 10, other n = 20. Results of surgery available for 56 oPts were: R0-R1: 85.7%, R2: 14.3%. The median time from BV initiation to first resection was 207 days. For oPts, BV was mainly associated with irinotecan-based regimens (97.0%) and with FOLFOX regimens (3.0%); for noPts it was: FOLFIRI: 83.6%, XELIRI: 2.9%, FOLFOX: 10.7%, XELOX: 2.5% and FOLFIRINOX: 0.4%. Objective response rate was 85.1% including 32.8% complete response (vs. 49.3% and 5.4% for noPts), stable disease 14.9% (vs. 30.0%) and absence of progressive disease (vs. 17.1%). Median duration of BV treatment was 6.9 months and of first-line therapy was 14.3 months (vs. 5.0 and 8.3 months for noPts). Median PFS was 13.6 months for oPts, the 1-yr OS rate was 94.0% (95%CI 84.9-97.7) and the 2-yr OS rate was 81.7% (95%CI 70.0-89.2) (vs. for noPts: median PFS 9.0 months, 1-yr OS rate 75.2% [95%CI 69.6-79.8] and the 2-yr OS rate 44.5% [95%CI 38.5-50.4]). Median OS was not reached for oPts and was 21.9 months for noPts. Conclusions: For pts treated by BV in a real-life setting, secondary resection of mCRC for initially unresectable metastases was possible for 19% of pts with 85.7% R0-R1. Evaluation of morbidity and longer follow-up will allow the real long-term benefit to be studied. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 15539
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) in metastatic gastric adenocarcinoma (MGA)
15539 Background: The most commonly used schedules for MGA are 5FU in combination with CDDP with or without Epirubicin (ECF) or Docetaxel (TCF). Irinotecan combined with 5FU (FOLFIRI regimen) was reported as active and well tolerated in a French randomized phase II study (Bouché, JCO 2004). The aim of this retrospective study was to evaluate the FOLFIRI regimen in a larger series of MGA patients (pts). Methods: Between 05/99 and 03/07, 219 pts from 13 French centers (162 males (72%), median age: 62 years, range: 25–88) were treated with at least one cycle of FOLFIRI. Primary tumour sites were 127 (58%) stomach and 92 (42%) gastroesophageal junction. The WHO status was 0 or 1 in 81% of pts and 95 (43%) pts were asymptomatic. One hundred forty two pts (65%) were treated in first- line (including 42 pts previously exposed to chemotherapy as (neo)adjuvant therapy). The 77 others pts (35%) received FOLFIRI as second- (n = 60) or later- (n=17) line for MGA. Results: Median number of chemotherapy cycles was 6 (range: 1–28). Grade 3 or 4 toxicities per patient were respectively: neutropenia 19%, mucositis 2%, nausea 5%, vomiting 6%, diarrhea 5%. There was one toxic death due to neutropenia. For the 147 pts treated as first-line, response rate was 34.7% (95% CI: 24.8 - 44.6, 92 measurable pts), median PFS was 5.8 months and median overall survival was 12.9 months (1-yr survival: 55%). For the 92 pts treated as second- or later-line, response rate was 18.2% (95% CI: 7.8 - 28.6, 55 measurable pts), median PFS was 4.0 months and median overall survival was 9.5 months (1-yr survival: 39%). Conclusions: These retrospective data 1- confirm the interesting activity and good tolerance of FOLFIRI regimen in MGA as first-line as well as later-line; 2- justify the ongoing prospective multicenter French phase III study, comparing FOLFIRI followed at progression by ECC (Epirubicine, Cisplatin, Capecitabine) versus the opposite sequence in MGA. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 15539
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) in metastatic gastric adenocarcinoma (MGA)
15539 Background: The most commonly used schedules for MGA are 5FU in combination with CDDP with or without Epirubicin (ECF) or Docetaxel (TCF). Irinotecan combined with 5FU (FOLFIRI regimen) was reported as active and well tolerated in a French randomized phase II study (Bouché, JCO 2004). The aim of this retrospective study was to evaluate the FOLFIRI regimen in a larger series of MGA patients (pts). Methods: Between 05/99 and 03/07, 219 pts from 13 French centers (162 males (72%), median age: 62 years, range: 25–88) were treated with at least one cycle of FOLFIRI. Primary tumour sites were 127 (58%) stomach and 92 (42%) gastroesophageal junction. The WHO status was 0 or 1 in 81% of pts and 95 (43%) pts were asymptomatic. One hundred forty two pts (65%) were treated in first- line (including 42 pts previously exposed to chemotherapy as (neo)adjuvant therapy). The 77 others pts (35%) received FOLFIRI as second- (n = 60) or later- (n=17) line for MGA. Results: Median number of chemotherapy cycles was 6 (range: 1–28). Grade 3 or 4 toxicities per patient were respectively: neutropenia 19%, mucositis 2%, nausea 5%, vomiting 6%, diarrhea 5%. There was one toxic death due to neutropenia. For the 147 pts treated as first-line, response rate was 34.7% (95% CI: 24.8 - 44.6, 92 measurable pts), median PFS was 5.8 months and median overall survival was 12.9 months (1-yr survival: 55%). For the 92 pts treated as second- or later-line, response rate was 18.2% (95% CI: 7.8 - 28.6, 55 measurable pts), median PFS was 4.0 months and median overall survival was 9.5 months (1-yr survival: 39%). Conclusions: These retrospective data 1- confirm the interesting activity and good tolerance of FOLFIRI regimen in MGA as first-line as well as later-line; 2- justify the ongoing prospective multicenter French phase III study, comparing FOLFIRI followed at progression by ECC (Epirubicine, Cisplatin, Capecitabine) versus the opposite sequence in MGA. No significant financial relationships to disclose.
- Open Access
- 4 September 2007
- Published by Elsevier in Annals of Oncology
- Vol. 18 (12) , 2000-2005
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
Background: To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer. Patients and methods: In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m2 and irinotecan 180 mg/m2 biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m2 in a 2-h infusion and bolus injection of 5FU 400 mg/m2 on day 1, then a two 400 mg/m2 continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m2 (20 patients) or irinotecan 180 mg/m2 (20 patients). Results: Twenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%. Conclusion: The IRINOX arm has a manageable toxicity and is active.
- 4 September 2007
- Published by Elsevier in Annals of Oncology
- Vol. 18 (12) , 2000-2005
Open AccessA randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
Background: To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer. Patients and methods: In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m2 and irinotecan 180 mg/m2 biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m2 in a 2-h infusion and bolus injection of 5FU 400 mg/m2 on day 1, then a two 400 mg/m2 continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m2 (20 patients) or irinotecan 180 mg/m2 (20 patients). Results: Twenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%. Conclusion: The IRINOX arm has a manageable toxicity and is active.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 3502
A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)
3502 Background: LV5FU2+CPT-11 has shown more activity than LV5FU2 alone in first line metastatic colorectal cancer. This adjuvant trial evaluated the addition of CPT-11 to LV5FU2 in terms of Event-Free Survival (EFS) and safety in colorectal cancer patients (pts) at a high risk of relapse. Methods: Colon cancer pts with postoperative N2 or N1 detected by occlusion/perforation were randomized to either: A: LV5FU2 (leucovorin 200mg/m2 as a 2-h infusion, 5-FU 400mg/m2 bolus and 600mg/m2 22-h continuous infusion, d1–2) or B: LV5FU2+CPT-11 (irinotecan 180mg/m2 90-min infusion d1+LV5FU2) fortnightly for 12 cycles without any support of growth factors. Pts were stratified by center, type of detection, delay from surgery to chemotherapy (≤28d; >28d) and age (<65y;≥65y). A 0.64 hazard ratio was deduced from an expected change in 3-year EFS from 45% to 60% with 5% two-sided alpha and 85% power. ITT survival analysis used the Logrank test. Results: 400 pts were randomized 1:1 in 75 centers between 11/98 and 09/02. Median follow-up is 36 months. More T3/T4 (p<0.017), more 15+ positives nodes (p<0.014), more vascular invasion (p<0.031), and more perineural involvement (p80% for 95% and 77% in arms A and B (p80% for 70% pts. More NCI G3–4 neutropenia in arm B (4% vs. 28%pts, p<0.001) is related to the absence of G-CSF support. In spite of only 97% necessary events observed, there was no significant difference in EFS rates between the 2 treatment arms. Conclusions: The two arms were unbalanced for important prognostic factors. Adjuvant LV5FU2+CPT-11 as compared to LV5FU2 alone is associated with more G3–4 neutropenia. These preliminary results show no improvement between the 2 arms in terms of EFS in the ITT analysis. Final analysis will be presented with more follow-up. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 3502
A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)
3502 Background: LV5FU2+CPT-11 has shown more activity than LV5FU2 alone in first line metastatic colorectal cancer. This adjuvant trial evaluated the addition of CPT-11 to LV5FU2 in terms of Event-Free Survival (EFS) and safety in colorectal cancer patients (pts) at a high risk of relapse. Methods: Colon cancer pts with postoperative N2 or N1 detected by occlusion/perforation were randomized to either: A: LV5FU2 (leucovorin 200mg/m2 as a 2-h infusion, 5-FU 400mg/m2 bolus and 600mg/m2 22-h continuous infusion, d1–2) or B: LV5FU2+CPT-11 (irinotecan 180mg/m2 90-min infusion d1+LV5FU2) fortnightly for 12 cycles without any support of growth factors. Pts were stratified by center, type of detection, delay from surgery to chemotherapy (≤28d; >28d) and age (<65y;≥65y). A 0.64 hazard ratio was deduced from an expected change in 3-year EFS from 45% to 60% with 5% two-sided alpha and 85% power. ITT survival analysis used the Logrank test. Results: 400 pts were randomized 1:1 in 75 centers between 11/98 and 09/02. Median follow-up is 36 months. More T3/T4 (p<0.017), more 15+ positives nodes (p<0.014), more vascular invasion (p<0.031), and more perineural involvement (p80% for 95% and 77% in arms A and B (p80% for 70% pts. More NCI G3–4 neutropenia in arm B (4% vs. 28%pts, p<0.001) is related to the absence of G-CSF support. In spite of only 97% necessary events observed, there was no significant difference in EFS rates between the 2 treatment arms. Conclusions: The two arms were unbalanced for important prognostic factors. Adjuvant LV5FU2+CPT-11 as compared to LV5FU2 alone is associated with more G3–4 neutropenia. These preliminary results show no improvement between the 2 arms in terms of EFS in the ITT analysis. Final analysis will be presented with more follow-up. No significant financial relationships to disclose.
- 1 June 2005
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 29 (6-7) , 667-675
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer
- 1 June 2005
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 29 (6-7) , 667-675
Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer
- 1 December 2001
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 40 (3) , 265-272
Oxaliplatin: available data in non-colorectal gastrointestinal malignancies
- 1 December 2001
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 40 (3) , 265-272
Oxaliplatin: available data in non-colorectal gastrointestinal malignancies
- 15 November 2001
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (22) , 4195-4201
Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients
PURPOSE: To assess antitumor activity and safety of two regimens in advanced colorectal cancer (CRC) patients with proven fluorouracil (5-FU) resistance in a randomized phase II study: 5-FU/folinic acid (FA) combined with alternating irinotecan (also called CPT-11) and oxaliplatin (FC/FO tritherapy), and an oxaliplatin/irinotecan (OC) combination. PATIENTS AND METHODS: Sixty-two patients were treated: arm FC/FO (32 patients) received, every 4 weeks, FA 200 mg/m2 followed by a 400-mg/m2 5-FU bolus injection, then a 600-mg/m2 continuous infusion of 5-FU on days 1 and 2 every 2 weeks administered alternately with irinotecan (180 mg/m2 on day 1) and oxaliplatin (85 mg/m2 on day 15). Arm OC (30 patients) received oxaliplatin 85 mg/m2 and irinotecan 200 mg/m2 every 3 weeks. RESULTS: In an intent-to-treat analysis, two partial responses lasting 10.7 and 16 months were observed with the tritherapy regimen, and seven (median duration, 11 months; range, 10.6 to 11.4 months) were observed with the bitherapy regimen. Median progression-free and overall survival times were 8.2 and 9.8 months, respectively, in the FC/FO arm and 8.5 and 12.3 months, respectively, in the OC arm. Main grade 3/4 toxicities were, respectively, neutropenia, 53% and 47%; febrile neutropenia, 13% and 3%; diarrhea, 19% and 10%; vomiting, 6% and 13%; and neurosensory toxicity, 3% and 3%. No treatment-related deaths occurred. CONCLUSION: The every-3-weeks OC combination is safe and active in advanced 5-FU–resistant CRC patients. The lower activity data seen with the tritherapy regimen may be related to the lower dose intensities of irinotecan and oxaliplatin in this schedule.
- 15 November 2001
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (22) , 4195-4201
Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients
PURPOSE: To assess antitumor activity and safety of two regimens in advanced colorectal cancer (CRC) patients with proven fluorouracil (5-FU) resistance in a randomized phase II study: 5-FU/folinic acid (FA) combined with alternating irinotecan (also called CPT-11) and oxaliplatin (FC/FO tritherapy), and an oxaliplatin/irinotecan (OC) combination. PATIENTS AND METHODS: Sixty-two patients were treated: arm FC/FO (32 patients) received, every 4 weeks, FA 200 mg/m2 followed by a 400-mg/m2 5-FU bolus injection, then a 600-mg/m2 continuous infusion of 5-FU on days 1 and 2 every 2 weeks administered alternately with irinotecan (180 mg/m2 on day 1) and oxaliplatin (85 mg/m2 on day 15). Arm OC (30 patients) received oxaliplatin 85 mg/m2 and irinotecan 200 mg/m2 every 3 weeks. RESULTS: In an intent-to-treat analysis, two partial responses lasting 10.7 and 16 months were observed with the tritherapy regimen, and seven (median duration, 11 months; range, 10.6 to 11.4 months) were observed with the bitherapy regimen. Median progression-free and overall survival times were 8.2 and 9.8 months, respectively, in the FC/FO arm and 8.5 and 12.3 months, respectively, in the OC arm. Main grade 3/4 toxicities were, respectively, neutropenia, 53% and 47%; febrile neutropenia, 13% and 3%; diarrhea, 19% and 10%; vomiting, 6% and 13%; and neurosensory toxicity, 3% and 3%. No treatment-related deaths occurred. CONCLUSION: The every-3-weeks OC combination is safe and active in advanced 5-FU–resistant CRC patients. The lower activity data seen with the tritherapy regimen may be related to the lower dose intensities of irinotecan and oxaliplatin in this schedule.